Risperdal Consta and Health Care Utilization in Patients With Schizophrenia

The purpose of this study is to determine if Risperdal Consta will affect the healthcare utilization costs in chronically ill schizophrenic patients with multiple admissions to the psychiatric hospital compared to the previous utilization costs under standard oral treatment of any atypical antipsychotic. We hypothesize that higher Risperdal Consta acquisition costs can be offset by reduction in total medical utilization costs, such as hospitalizations, ER visits, unscheduled outpatient visits or incarcerations due to worsening of psychotic symptoms.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Schizophrenia Mental Disorders Psychotic Disorders Schizoaffective Disorder Schizophrenia Spectrum and Other Psychotic Disorders

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Grady Hospital

Atlanta, Georgia, United States

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Primary diagnosis of schizophrenia or schizoaffective disorder
4 or more admissions to psychiatric hospital in past year, OR minimum of 2 hospital admissions and at least 2 incarcerations in the previous year
Medicaid recipient
Patients requiring concomitant non-antipsychotic psychotropic medication (mood stabilizing, antidepressants, anxiolytics)

Exclusion criteria

Past or current psychiatric disorder, other than schizophrenia or schizoaffective disorder
Drug or alcohol dependence
Serious, unstable medical illness or any acute medical condition
Pregnant or lactating females
Prior Risperdal Consta treatment
Non-English speaking

Treatment and study plan

RISPERDAL CONSTA

Drug

Sponsors and collaborators

Lead sponsor

Emory University

Other

Collaborators

Janssen, L.P. - Investigator Initiated Studies Program

Registry information

Official study title

The Effects of Risperdal Consta on Health Care Utilization Costs in Chronically Ill Schizophrenic Patients

Important dates

Study start: 2005
Primary completion: 2007
First posted: Apr 12, 2006
Registry last updated: Sep 25, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed